Plena Global Solidifies Position as Global Leader in B2B and B2W Medical Cannabis Markets

  • Colombian subsidiary of Plena Global to ship THC distillate to Portugal 
  • Continued validation of Plena Global’s global supply chain strategy 
  • Leading Colombian producer at scale 

 

July 8th, 2020 

Plena Global Holdings Inc. (“Plena Global”) is pleased to announce that its wholly owned Colombian subsidiary, Econnabis SAS, has entered into a letter of intent (the “LOI”) to supply 200 litres of GMP grade THC distillate to EXMceuticals (CSE: EXM / “EXM”) in Portugal. Jonathan Summers, EXM’s CEO, announced the completion of the LOI for THC distillate for use in its proposed facility in Portugal on June 12, 2020. 

This announcement is further validation of Plena Global’s position as a leading global business to business “B2B and business to wholesale B2W supplier of high quality, medical grade cannabis. 

“Last year, Plena shipped commercial medical cannabis products to Germany and the Netherlands, as well as other locations around the globe. This latest order into Portugal is yet another milestone as we continue to develop our channels as a premium B2B medical cannabis supplier to the world” stated Richard Zwicky, Plena Global’s CEO.   

Plena Global’s operational facility in Colombia is currently operating in the LATAM market and is operating towards GACP and GMP compliance standards. The Colombian facility is on track to ship from Colombia to the world and is positioned as a leading B2B and B2W medical cannabis supplier to pharmaceutical companies and licensed cannabis producers globally. 

Jonathan Summers, EXM’s CEO stated “We have gotten to know the team at Plena over the last few months and are impressed with the operation they have established. EXM does not cultivate cannabis in-house and relies on professional partners for the supply of raw material and semi-finished product. Europe offers a substantial medium-term opportunity for the sale of quality medical cannabinoids. We anticipate that this LOI for 200 liters is the first of many such orders with Plena Global.” 

Plena Global’s commitment to the B2B and B2W strategy and process development has been paramount in its development so far. Part of this strategy has led to the development of Plena Global’s PharmaHub strategy, which allows Plena to utilize its own production to create formulations and work with internationally recognized pharmaceutical partners to manufacture and export finished products to Plena Global’s international clients. Creation of the PharmaHub strategy will enable Plena Global to utilize the pharmaceutical sector to provide medical practitioners with dosage-controlled encapsulation options that keepatients needs top of mind.  

 

 

About Plena Global  

 Plena Global is a global B2B and B2W cannabis production company, headquartered in Victoria, British Columbia, Canada with a focus on supplying medical-grade cannabis products to licensed producers, pharmaceutical companies, manufacturers and distributors worldwide. With landholdings strategically located in South America, Plena Global can scale cultivation and production operations in optimal growing environments. 

For more information about Plena Global, visit its website at www.plena.global 

 

 

Cautionary Statement on Forward Looking Information  

 Certain information in this press release constitutes “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is neither historical fact nor assurance of future performance. Instead, such information is based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking information relates to, among other things, our future financial performance, financial condition, liquidity, levels of activity, performance, prospects, growth, goals or achievements or other future events. In some cases, forward looking information can be identified by the use of forward looking terminology such as “plans”, “assumes”, “targets”, “expects”, or “does not expect”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”.   

  Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, the company disclaims any obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. 

 

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on LinkedIn
Share on pinterest
Share on Pinterest

Leave a comment

Contact Us

Learn more about the medical-grade cannabis products we produce